InsiderSignal.AI

InsiderSignal.ai

HEPA - Hepion Pharmaceuticals, Inc.

Insider Purchase by Purcell Michael J. (Dir)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

1 week ago, Purcell Michael J., serving as Dir at Hepion Pharmaceuticals, Inc. (HEPA), purchased 1,250,000 shares at $0.04 per share, for a total transaction value of $50,000.00. Following this transaction, Purcell Michael J. now holds 1,250,000 shares of HEPA.

The trade was executed on Tuesday, April 21, 2026 and publicly disclosed via SEC Form 4 filing on Monday, April 27, 2026, 6 days after the trade was made.

Hepion Pharmaceuticals, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Purcell Michael J.

Dir

Michael J. Purcell is a seasoned financial executive and certified public accountant with over 37 years of experience at Deloitte & Touche LLP, where he served as an Audit Partner from 1979 to 2015 and as a consultant from 2015 to 2017.[[1]](https://hepionpharma.com/about/board/)[[2]](https://hepionpharma.com/news/hepion-pharmaceuticals-strengthens-board-of-directors-with-appointment-of-michael-purcell/) He provides assurance and advisory services to public and private companies and currently acts as a financial advisor to several emerging growth companies. Purcell holds a Master’s in Business Administration from Drexel University, a Bachelor of Science from Lehigh University, and is a member of the American Institute of Certified Public Accountants and the Pennsylvania Institute of Certified Public Accountants.[[1]](https://hepionpharma.com/about/board/)[[2]](https://hepionpharma.com/news/hepion-pharmaceuticals-strengthens-board-of-directors-with-appointment-of-michael-purcell/) Purcell was appointed as a Director of Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA), a clinical-stage biopharmaceutical company focused on NASH and fibrotic diseases, effective March 5, 2024.[[2]](https://hepionpharma.com/news/hepion-pharmaceuticals-strengthens-board-of-directors-with-appointment-of-michael-purcell/) His prior board experience includes serving as a director of Tabula Rasa HealthCare, Inc. from 2018 and chairman from 2022 until its 2023 acquisition by Nautic Partners; director of CFG Bank since 2016; director of Hyperion Bank since 2018; and director of International Money Express, Inc. since 2018.[[1]](https://hepionpharma.com/about/board/)[[2]](https://hepionpharma.com/news/hepion-pharmaceuticals-strengthens-board-of-directors-with-appointment-of-michael-purcell/)[[3]](https://www.gurufocus.com/insider/72376/michael-j.-purcell)[[7]](https://www.marketscreener.com/insider/MICHAEL-PURCELL-A258WV/) He also serves on boards of academic and community organizations.[[2]](https://hepionpharma.com/news/hepion-pharmaceuticals-strengthens-board-of-directors-with-appointment-of-michael-purcell/)

View full insider profile →

Trade Price

$0.04

Quantity

1,250,000

Total Value

$50,000.00

Shares Owned

1,250,000

Trade Date

Tuesday, April 21, 2026

9 days ago

SEC Filing Date

Monday, April 27, 2026

Filed 6 days after trade

HEALTHCAREBIOTECHNOLOGY

Discussion

Sign in to join the discussion.
Loading comments…
View news mentioning HEPA

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5995555

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime